JP2008528510A5 - - Google Patents

Download PDF

Info

Publication number
JP2008528510A5
JP2008528510A5 JP2007552335A JP2007552335A JP2008528510A5 JP 2008528510 A5 JP2008528510 A5 JP 2008528510A5 JP 2007552335 A JP2007552335 A JP 2007552335A JP 2007552335 A JP2007552335 A JP 2007552335A JP 2008528510 A5 JP2008528510 A5 JP 2008528510A5
Authority
JP
Japan
Prior art keywords
composition
weight gain
administration
activating compound
flush
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007552335A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008528510A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/002267 external-priority patent/WO2006079021A2/en
Publication of JP2008528510A publication Critical patent/JP2008528510A/ja
Publication of JP2008528510A5 publication Critical patent/JP2008528510A5/ja
Withdrawn legal-status Critical Current

Links

JP2007552335A 2005-01-20 2006-01-20 紅潮および/または薬物誘発性体重増加を処置するためのサーチュイン活性化化合物の使用 Withdrawn JP2008528510A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64591605P 2005-01-20 2005-01-20
US64596205P 2005-01-21 2005-01-21
PCT/US2006/002267 WO2006079021A2 (en) 2005-01-20 2006-01-20 Use of sirtuin-activating compounds for treating flushing and drug induced weight gain

Publications (2)

Publication Number Publication Date
JP2008528510A JP2008528510A (ja) 2008-07-31
JP2008528510A5 true JP2008528510A5 (cg-RX-API-DMAC7.html) 2009-01-29

Family

ID=36578920

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007552335A Withdrawn JP2008528510A (ja) 2005-01-20 2006-01-20 紅潮および/または薬物誘発性体重増加を処置するためのサーチュイン活性化化合物の使用

Country Status (6)

Country Link
US (1) US20060276416A1 (cg-RX-API-DMAC7.html)
EP (1) EP1841415A2 (cg-RX-API-DMAC7.html)
JP (1) JP2008528510A (cg-RX-API-DMAC7.html)
AU (1) AU2006206274A1 (cg-RX-API-DMAC7.html)
CA (1) CA2595486A1 (cg-RX-API-DMAC7.html)
WO (1) WO2006079021A2 (cg-RX-API-DMAC7.html)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050096256A1 (en) 2003-07-01 2005-05-05 President And Fellows Of Harvard College Compositions for manipulating the lifespan and stress response of cells and organisms
US20090169585A1 (en) * 2003-10-23 2009-07-02 Resveratrol Partners, Llc Resveratrol-Containing Compositions And Their Use In Modulating Gene Product Concentration Or Activity
US20050158376A1 (en) * 2003-10-23 2005-07-21 Sardi William F. Dietary supplement and method of processing same
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
EP1708689A2 (en) * 2003-12-29 2006-10-11 The President and Fellows of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
AU2005207029B2 (en) * 2004-01-20 2011-09-01 Brigham Young University Novel sirtuin activating compounds and methods for making the same
CN1964627B (zh) * 2004-06-04 2011-10-19 华盛顿大学 治疗神经病变的方法和组合物
UA91341C2 (ru) 2004-07-15 2010-07-26 Амр Текнолоджи, Інк. Арил- и гетероарилзамещенные тетрагидроизохинолины и их применение для блокирования обратного захвата норэпинефрина, допамина и серотонина
AU2006204699B2 (en) * 2005-01-13 2012-04-26 Sirtris Pharmaceuticals, Inc. Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
WO2006104586A2 (en) * 2005-02-15 2006-10-05 Joslin Diabetes Center Methods of diagnosis and treatment of metabolic disorders
US20090142335A1 (en) * 2005-02-15 2009-06-04 Joslin Diabetes Center Methods of diagnosis and treatment of metabolic disorders
EP2805719A1 (en) * 2005-03-30 2014-11-26 Glaxosmithkline LLC Nicotinamide riboside and analogues thereof
US20070014833A1 (en) * 2005-03-30 2007-01-18 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
AP2007004244A0 (en) 2005-05-10 2007-12-31 Intermune Inc Method of modulating stress-activated protein kinase system
US8546423B2 (en) 2005-05-18 2013-10-01 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US20060292099A1 (en) * 2005-05-25 2006-12-28 Michael Milburn Treatment of eye disorders with sirtuin modulators
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
US20070149466A1 (en) * 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
CN101176786A (zh) * 2006-11-08 2008-05-14 中国科学院上海生命科学研究院 增加胰岛素敏感性的方法和组合物
WO2008060400A2 (en) * 2006-11-15 2008-05-22 Sirtris Pharmaceuticals, Inc. Sirtuin polymorphisms and methods of use thereof
SG178716A1 (en) * 2007-01-16 2012-03-29 Ipintl Llc Novel composition for treating metabolic syndrome
WO2008119070A1 (en) * 2007-03-28 2008-10-02 Trustees Of Boston University Methods of treatment using sirt modulators and compositions containing sirt1 modulators
US8404275B2 (en) * 2007-07-01 2013-03-26 Vitalis Llc Combination tablet with chewable outer layer
WO2009005803A1 (en) * 2007-07-01 2009-01-08 Joseph Peter Habboushe Combination tablet with chewable outer layer
EP2018861A1 (en) * 2007-07-26 2009-01-28 Laboratorios del Dr. Esteve S.A. 5HT6-Ligands such as sulfonamide derivatives in drug-induced weight-gain
JP5337405B2 (ja) 2007-09-17 2013-11-06 ザ・ホスピタル・フォー・シック・チルドレン ゴーシェ病の治療方法
WO2009111031A2 (en) * 2008-03-04 2009-09-11 Intra-Cellular Therapies, Inc. Methods of treating vasomotor symptoms
CN102088965B (zh) * 2008-05-13 2013-05-08 根梅迪卡治疗公司 水杨酸盐(酯)缀合物在制备用于治疗代谢性病症的药物中的应用
CA2666036C (en) * 2008-05-16 2017-09-12 Chien-Hung Chen Novel compositions and methods for treating hyperproliferative diseases
EP2296653B1 (en) 2008-06-03 2016-01-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
WO2010011836A2 (en) * 2008-07-25 2010-01-28 Emory University Treating various disorders with 7,8-dihydroxyflavone and derivatives thereof
CN102325532B (zh) 2008-10-07 2015-06-17 Mpex医药有限公司 用于减轻肺部炎症的左氧氟沙星吸入剂
AU2009302478B2 (en) * 2008-10-07 2015-09-03 Horizon Orphan Llc Aerosol fluoroquinolone formulations for improved pharmacokinetics
WO2010107702A1 (en) * 2009-03-16 2010-09-23 Ipintl, Llc Treating alzheimer's disease and osteoporosis and reducing aging
JP2012520342A (ja) * 2009-03-16 2012-09-06 ジェンメディカ・セラピューティックス・ソシエダッド・リミターダ 代謝障害を処置するのに有用な抗炎症剤および抗酸化剤のコンジュゲート
CN102421424A (zh) * 2009-03-16 2012-04-18 根梅迪卡治疗公司 用于治疗代谢性疾病的组合疗法
CN102595902B (zh) * 2009-05-12 2015-04-29 阿尔巴尼分子研究公司 7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉及其用途
ES2446971T3 (es) 2009-05-12 2014-03-11 Albany Molecular Research, Inc. Tetrahidroisoquinolinas sustituidas con arilo, heteroarilo, y heterociclo y su uso
JP5739415B2 (ja) 2009-05-12 2015-06-24 ブリストル−マイヤーズ スクウィブ カンパニー (S)−7−([1,2,4]トリアゾロ[1,5−a]ピリジン−6−イル)−4−(3,4−ジクロロフェニル)−1,2,3,4−テトラヒドロイソキノリンの結晶形態およびその使用
WO2011002673A1 (en) * 2009-07-01 2011-01-06 Temple University - Of The Commonwealth System Of Higher Education Leptin agonist and methods of use
DK2473504T3 (en) 2009-09-03 2015-03-16 Bioenergenix Heterocyclic Compounds for Inhibition of Passover
LT2473170T (lt) 2009-09-04 2019-10-10 Horizon Orphan Llc Aerozolizuoto levofloksacino panaudojimas cistinės fibrozės gydymui
FI20106119A0 (fi) * 2010-10-27 2010-10-27 Sirtuin Valley Oy Energia-aineenvaihduntaan vaikuttava koostumus
US8466197B2 (en) 2010-12-14 2013-06-18 Genmedica Therapeutics Sl Thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders
WO2012094462A2 (en) 2011-01-05 2012-07-12 Bioenergenix Heterocyclic compounds for the inhibition of pask
US8916561B2 (en) 2011-03-02 2014-12-23 Bioenergenix, Llc Substituted quinoxaline compounds for the inhibition of PASK
WO2012119046A2 (en) 2011-03-02 2012-09-07 Bioenergenix Heterocyclic compounds for the inhibition of pask
JP6140682B2 (ja) * 2011-04-15 2017-05-31 ネステク ソシエテ アノニム サーチュイン遺伝子発現の調節方法
JP2012236793A (ja) * 2011-05-11 2012-12-06 Kikkoman Corp Ampk活性化剤
MX2014000419A (es) 2011-07-15 2014-09-22 Nusirt Sciences Inc Composicones y metodos para modular trayectorias metabolicas.
WO2013063078A1 (en) 2011-10-28 2013-05-02 Vitalis Llc Anti-flush compositions
WO2013074948A1 (en) 2011-11-16 2013-05-23 Resveratrol Partners, Llc Compositions containing resveratrol and nucleotides
US9745279B2 (en) 2011-12-27 2017-08-29 Tokiwa Phytochemical Co., Ltd. Sirtuin activator
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
TWI485145B (zh) 2012-10-26 2015-05-21 財團法人工業技術研究院 P型有機半導體材料與光電元件
BR112015010947A2 (en) 2012-11-13 2018-06-05 Nusirt Sciences, Inc. compositions and methods for increasing energy metabolism.
SG11201507046UA (en) * 2013-03-15 2015-10-29 Nusirt Sciences Inc Leucine and nicotinic acid reduces lipid levels
EP2801357A1 (en) 2013-05-10 2014-11-12 IMD Natural Solutions GmbH Carboxylated stilbenes for activating AMPK and sirtuins
RU2692485C2 (ru) 2014-04-02 2019-06-25 Интермьюн, Инк. Противофиброзные пиридиноны
AU2016219879A1 (en) * 2015-02-19 2017-08-24 Purdue Pharma L.P. Methods and compositions for decreasing gastric emptying
CN105153090A (zh) * 2015-07-17 2015-12-16 浙江海洋学院 4′-溴-7-异戊烯氧基-2,3-二氢黄酮和制备方法以及在制备抗抑郁药物中的应用
CN105380955A (zh) * 2015-09-24 2016-03-09 成都普瑞法科技开发有限公司 土大黄苷在治疗溃疡性结肠炎药物中的应用
US20180169085A1 (en) * 2016-12-19 2018-06-21 Augusta University Reserch Institute, Inc. Combination Therapy for Hemorrhagic Injury
WO2019108877A1 (en) * 2017-12-01 2019-06-06 University Of Hawaii GSK-3β INHIBITORS AND USE THEREOF IN METHODS OF TREATMENT
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
IT201900003325A1 (it) * 2019-03-07 2020-09-07 C I A M S R L Composizione per la prevenzione e trattamento della dermatite atopica
WO2021096882A1 (en) * 2019-11-11 2021-05-20 Nusirt Sciences, Inc. Compositions, methods and kits for altering adipocytes
KR20240101561A (ko) 2021-10-14 2024-07-02 인사이트 코포레이션 Kras의 저해제로서의 퀴놀린 화합물
WO2025049514A1 (en) * 2023-08-30 2025-03-06 Sirona Biosciences Inc. Compositions and methods with flavonoids

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827898A (en) * 1996-10-07 1998-10-27 Shaman Pharmaceuticals, Inc. Use of bisphenolic compounds to treat type II diabetes
KR20010031501A (ko) * 1997-10-31 2001-04-16 추후제출 5-알파 환원효소 활성을 조절하는 방법 및 조성물
US6331633B1 (en) * 1998-05-08 2001-12-18 Calyx Therapeutics Inc. Heterocyclic analogs of diphenylethylene compounds
US6448450B1 (en) * 1998-05-08 2002-09-10 Calyx Therapeutics, Inc. 1-(3,5-dimethoxyphenyl)-2-(4-hydroxyphenyl)-ethylene for diabetes treatment
US7452664B2 (en) * 1999-12-15 2008-11-18 Massachusetts Institute Of Technology Methods for identifying agents which alter histone protein acetylation
US20010039296A1 (en) * 2000-03-23 2001-11-08 Debasis Bagchi Method and composition for preventing or reducing the symptoms of menopause
US6475530B1 (en) * 2000-05-31 2002-11-05 Eric H. Kuhrts Methods and compositions for producing weight loss
US6552085B2 (en) * 2000-08-16 2003-04-22 Insmed Incorporated Compositions containing hypoglycemically active stilbenoids
KR100407399B1 (ko) * 2000-08-22 2003-11-28 주식회사 뉴로넥스 세로토닌 n-아세틸트란스퍼라제의 활성 억제제
IT1320080B1 (it) * 2000-10-25 2003-11-18 Giuliani Spa Composizione per uso farmaceutico o dietetico.
WO2002040021A2 (en) * 2000-11-17 2002-05-23 Idenix (Cayman) Limited Methods for inhibiting the transmission of hiv using topically applied substituted 6-benzyl-4-oxopyrimidines
BR0204228A (pt) * 2001-02-20 2004-06-22 Randy Ziegler Métodos para melhorar os sintomas de uma psicose e de esquizofrenia e para triar moléculas de teste, e, composto orgânico
GB0123991D0 (en) * 2001-10-05 2001-11-28 Arachnova Ltd New therapeutic use
JPWO2004096198A1 (ja) * 2003-05-02 2006-07-13 タカラバイオ株式会社 治療剤
AU2004249124A1 (en) * 2003-05-20 2004-12-29 Erimos Pharmaceuticals Llc Methods and compositions for delivery of catecholic butanes for treatment of diseases
US20050096256A1 (en) * 2003-07-01 2005-05-05 President And Fellows Of Harvard College Compositions for manipulating the lifespan and stress response of cells and organisms
US20050136429A1 (en) * 2003-07-03 2005-06-23 Massachusetts Institute Of Technology SIRT1 modulation of adipogenesis and adipose function
EP1708689A2 (en) * 2003-12-29 2006-10-11 The President and Fellows of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
US7838503B2 (en) * 2005-06-15 2010-11-23 Children's Medical Center Corporation Methods for extending the replicative lifespan of cells

Similar Documents

Publication Publication Date Title
KR101900989B1 (ko) 정신분열증 치료에서의 4-((1r,3s)-6-클로로-3-페닐-인단-1-일)-1,2,2-트리메틸-피페라진 및 그 염의 투여 방법
JP2019052154A5 (cg-RX-API-DMAC7.html)
HRP20200828T1 (hr) Farmaceutski pripravak koji sadrži sglt2-inhibitor, dpp-iv-inhibitor i prema potrebi jedno dodatno antidijabetičko sredstvo, te njegove uporabe
BRPI0818687A2 (pt) composto espiro, o sal deste farmaceuticamente aceitavél ou o solvato deste, composição farmacêutica, medicamento agonista de gpr40, agente promotor da secreção de insulina ou um agente hipoglicêmico, uso do composto espíro, o sal deste farmaceuticamente aceitavél ou o solvato deste, e, métodos para a ativação de gpr40, para promover secreção de insulina ou diminuir o nível de glicose sanguínea, e para tratar ou prevenir uma doença.
US20180000768A1 (en) Intestinal fxr agonism enhances glp-1 signaling to restore pancreatic beta cell functions
BRPI0711872A2 (pt) tratamento para distúrbios depressivos
TW202128168A (zh) 法匹拉韋在治療冠狀病毒感染方面的應用
EP1858516A1 (en) Pharmaceutical compositions for the treatment and/or prevention of depression
CO6251239A2 (es) Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo junto con un inhibidor de dpp iv
JP2010535252A5 (cg-RX-API-DMAC7.html)
JP2010534676A5 (cg-RX-API-DMAC7.html)
BRPI0712039A2 (pt) uso de flibanserina para o tratamento de distúrbios de desejo sexual pós-menopausa
JP2009531435A (ja) うつ病の治療用の新規な治療組み合わせ
HRP20131120T1 (hr) Farmaceutski pripravak koji sadrži (1s)-1,5-anhidro-1-[5-(4-etoksibenzil)-2-metoksi-4-metilfenil]-1-tio-d-glucitol i metformin, te njegova uporaba za lijeäśenje dijabetesa
JP2008536946A (ja) うつ病の処置または予防のための新規の治療的組み合わせ
HRP20171739T1 (hr) Postupci i kompozicije za liječenje simptoma povezanih s posttraumatskim stresnim poremećajem korištenjem ciklobenzaprina
WO1999061027A1 (en) Combination therapy for treatment of refractory depression
Yoshino et al. Perospirone, a novel atypical antipsychotic drug, potentiates fluoxetine-induced increases in dopamine levels via multireceptor actions in the rat medial prefrontal cortex
NO20091644L (no) Hurtig desintegrerende, lyofiliserte orale formuleringer av en trombinreseptorantagonist
DeBattista et al. Utility of atypical antipsychotics in the treatment of resistant unipolar depression
JP2011512347A5 (cg-RX-API-DMAC7.html)
Yoshino et al. Oseltamivir (Tamiflu®) increases dopamine levels in the rat medial prefrontal cortex
JP2013525460A5 (cg-RX-API-DMAC7.html)
JP2013032308A5 (cg-RX-API-DMAC7.html)
JP2007505156A5 (cg-RX-API-DMAC7.html)